New treatment alert! The FDA recently approved Tapinarof, applied as a cream, for kids 2 years and up. We ask Dr. Leon Kircik from Icahn School of Medicine, NY, who led the clinical trials about the safety, efficacy and side effects of Tapinarof. And because we are parents too, we ask: How quickly does it work? Can you start/stop it as needed? How easy will it be to access? And more. If you like our podcast, please consider supporting it with a tax deductible donation.

Research discussed

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

Tapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysis

Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs

What to look out for in eczema moisturizers, why eczema babies have rosy red cheeks and can allergies transfer to baby from breast milk? Join Korey Capozza, Dr. Jessica Hui-Beckman (National Jewish Health) and Dr. Kirsi Jarvinen-Seppo (University of Rochester) to find the answers. If you like our podcast, please consider supporting it with a tax deductible donation.

Research discussed

Consumer Preferences, Product Characteristics, and Potentially Allergenic Ingredients in Best-selling Moisturizers

Early Life Cheek Skin Barrier Changes are Associated with Atopic Dermatitis Development

Prevention of IgE-Mediated Food Allergy: Emerging Strategies Through Maternal and Neonatal Interventions

Could injectable drugs called "biologics" stop eczema by teaching a child's developing immune system to be less reactive? Dr. Amy Paller from Northwestern University Chicago and Dr. Elaine Siegfried from Saint Louis University in Missouri discuss stopping or tapering biologics and what happens to the immune system when we are on them. If you like our podcast, please consider supporting it with a tax deductible donation.

Research discussed

Clinical remission and therapy-free remission in pediatric patients with moderate-to-severe atopic dermatitis treated with dupilumab

Factors Associated with Remission of Eczema in Children

Persistence of Mild to Moderate Atopic Dermatitis

Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children